Sensei biotherapeutics reports second quarter 2023 financial results and recent business highlights

Phase 1/2 clinical trial enrolling for lead investigational candidate sns-101, a conditionally active vista-blocking antibody for the treatment of advanced solid tumors

SNSE Ratings Summary

SNSE Quant Ranking